Wright & Schulte LLC is Evaluating AndroGel lawsuits on Behalf of Men Who Suffered Potentially Life-Threatening Cardiovascular Problems, Including Heart Attacks and Strokes, Allegedly Due to Their Use of the Low Testosterone Therapy.
Wright & Schulte LLC, an experienced law firm representing clients in AndroGel lawsuits, announces they have launched a new Facebook page to provide the public with the most up-to-date information regarding the growing litigation of product liability claims involving this low testosterone therapy. The new Facebook page will operate as an adjunct to Wright & Schulte’s main website, and serve as another avenue for clients, potential clients and others who may have questions about the life-threatening heart side effects allegedly associated with AndroGel. In addition to accessing important information regarding the mounting number of AndroGel lawsuit filings, visitors to the page will be able to link to Wright & Schulte’s website, share their own experiences with this medication, and interact with the Firm’s attorneys. Visitors are invited to “Like” the AndroGel lawsuit page to help spread the word about this important legal and public health issue.
AndroGel is a topical medication approved to treat hypogonadism (low testosterone) in men who suffer from the condition due to an underlying medical issue. According to court documents, more than 30 AndroGel lawsuits have been filed in courts around the country on behalf of men who allegedly suffered heart attacks, strokes, heart failure, deep vein thrombosis, pulmonary embolism, and other cardiovascular problems due to their use of the medication. On March 28, 2014, plaintiffs filed a brief with the U.S. Judicial Panel on Multidistrict Litigation requesting that all federal AndroGel lawsuits be consolidated and transferred to a single judge in the U.S. District Court, Northern District of Illinois. Among other things, the brief asserted that the consolidation of the cases is warranted, as hundreds of similar AndroGel lawsuits could ultimately be filed in U.S. Courts. (In Re: AndroGel Product Liability Litigation, MDL Docket No. 36 ).
On January 31, 2014, the U.S. Food & Drug Administration (FDA) announced it had launched a safety review of drugs like AndroGel, after two studies indicated that testosterone therapy might increase the risk of heart attacks, strokes and death in older men or men with pre-existing heart problems. According to court documents, plaintiffs in AndroGel lawsuits claim that the drug was wrongly marketed as being safe and effective, and accuse AbbVie Inc. of engaging in an aggressive marketing campaign that prompted men to seek low testosterone therapy to alleviate low libido, fatigue and other issues associated with aging. They further allege that the company’s AndroGel marketing tactics resulted in many men being prescribed AndroGel without an actual medical diagnosis of low testosterone.
[fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014]
Men who used this low testosterone therapy or a similar drug may be eligible to file their AndroGel lawsuit if they experienced serious and life-threatening cardiovascular events during treatment. To learn more, or to arrange for a free legal consultation with an attorney at Wright & Schulte LLC, please visit yourlegalhelp.com.
About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Lipitor lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377
Like Us on Facebook
Follow Us on Twitter